Haemophilia  ||| S:0 E:12 ||| JJ
registry  ||| S:12 E:21 ||| NN
of  ||| S:21 E:24 ||| IN
the  ||| S:24 E:28 ||| DT
medical  ||| S:28 E:36 ||| JJ
committee  ||| S:36 E:46 ||| NN
of  ||| S:46 E:49 ||| IN
the  ||| S:49 E:53 ||| DT
swiss  ||| S:53 E:59 ||| JJ
haemophilia  ||| S:59 E:71 ||| JJ
society  ||| S:71 E:79 ||| NN
The  ||| S:79 E:83 ||| DT
Swiss  ||| S:83 E:89 ||| JJ
Haemophilia  ||| S:89 E:101 ||| NNP
Registry  ||| S:101 E:110 ||| NNP
of  ||| S:110 E:113 ||| IN
the  ||| S:113 E:117 ||| DT
Medical  ||| S:117 E:125 ||| NNP
Committee  ||| S:125 E:135 ||| NNP
of  ||| S:135 E:138 ||| IN
the  ||| S:138 E:142 ||| DT
Swiss  ||| S:142 E:148 ||| JJ
Haemophilia  ||| S:148 E:160 ||| NNP
Society  ||| S:160 E:168 ||| NNP
was  ||| S:168 E:172 ||| VBD
established  ||| S:172 E:184 ||| VBN
in  ||| S:184 E:187 ||| IN
2000 ||| S:187 E:191 ||| CD
.  ||| S:191 E:193 ||| .
Primarily  ||| S:193 E:203 ||| RB
it  ||| S:203 E:206 ||| PRP
bears  ||| S:206 E:212 ||| VBZ
epidemiological  ||| S:212 E:228 ||| VBN
and  ||| S:228 E:232 ||| CC
basic  ||| S:232 E:238 ||| JJ
clinical  ||| S:238 E:247 ||| JJ
data  ||| S:247 E:252 ||| NNS
( ||| S:252 E:253 ||| -LRB-
incidence ||| S:253 E:262 ||| NN
,  ||| S:262 E:264 ||| ,
type  ||| S:264 E:269 ||| NN
and  ||| S:269 E:273 ||| CC
severity  ||| S:273 E:282 ||| NN
of  ||| S:282 E:285 ||| IN
the  ||| S:285 E:289 ||| DT
disease ||| S:289 E:296 ||| NN
,  ||| S:296 E:298 ||| ,
age  ||| S:298 E:302 ||| NN
groups ||| S:302 E:308 ||| NNS
,  ||| S:308 E:310 ||| ,
centres ||| S:310 E:317 ||| NN
,  ||| S:317 E:319 ||| ,
mortality ||| S:319 E:328 ||| NN
) ||| S:328 E:329 ||| -RRB-
.  ||| S:329 E:331 ||| .
Two  ||| S:331 E:335 ||| CD
thirds  ||| S:335 E:342 ||| NNS
of  ||| S:342 E:345 ||| IN
the  ||| S:345 E:349 ||| DT
questions  ||| S:349 E:359 ||| NNS
of  ||| S:359 E:362 ||| IN
the  ||| S:362 E:366 ||| DT
WFH  ||| S:366 E:370 ||| NNP
Global  ||| S:370 E:377 ||| NNP
Survey  ||| S:377 E:384 ||| NNP
can  ||| S:384 E:388 ||| MD
be  ||| S:388 E:391 ||| VB
answered ||| S:391 E:399 ||| VBN
,  ||| S:399 E:401 ||| ,
especially  ||| S:401 E:412 ||| RB
those  ||| S:412 E:418 ||| DT
concerning  ||| S:418 E:429 ||| JJ
use  ||| S:429 E:433 ||| NN
of  ||| S:433 E:436 ||| IN
concentrates  ||| S:436 E:449 ||| NNS
( ||| S:449 E:450 ||| -LRB-
global ||| S:450 E:456 ||| JJ
,  ||| S:456 E:458 ||| ,
per  ||| S:458 E:462 ||| IN
capita ||| S:462 E:468 ||| NN
)  ||| S:468 E:470 ||| -RRB-
and  ||| S:470 E:474 ||| CC
treatment  ||| S:474 E:484 ||| NN
modalities  ||| S:484 E:495 ||| NNS
( ||| S:495 E:496 ||| -LRB-
on-demand  ||| S:496 E:506 ||| FW
versus  ||| S:506 E:513 ||| FW
prophylactic  ||| S:513 E:526 ||| FW
regimens ||| S:526 E:534 ||| FW
) ||| S:534 E:535 ||| -RRB-
.  ||| S:535 E:537 ||| .
Moreover ||| S:537 E:545 ||| RB
,  ||| S:545 E:547 ||| ,
the  ||| S:547 E:551 ||| DT
registry  ||| S:551 E:560 ||| NN
is  ||| S:560 E:563 ||| VBZ
an  ||| S:563 E:566 ||| DT
important  ||| S:566 E:576 ||| JJ
tool  ||| S:576 E:581 ||| NN
for  ||| S:581 E:585 ||| IN
quality  ||| S:585 E:593 ||| NN
control  ||| S:593 E:601 ||| NN
of  ||| S:601 E:604 ||| IN
the  ||| S:604 E:608 ||| DT
haemophilia  ||| S:608 E:620 ||| JJ
treatment  ||| S:620 E:630 ||| NN
centres ||| S:630 E:637 ||| NN
.  ||| S:637 E:639 ||| .
There  ||| S:639 E:645 ||| EX
are  ||| S:645 E:649 ||| VBP
no  ||| S:649 E:652 ||| DT
informations  ||| S:652 E:665 ||| NN
about  ||| S:665 E:671 ||| IN
infectious  ||| S:671 E:682 ||| JJ
diseases  ||| S:682 E:691 ||| NNS
like  ||| S:691 E:696 ||| IN
hepatitis  ||| S:696 E:706 ||| NNP
or  ||| S:706 E:709 ||| CC
HIV ||| S:709 E:712 ||| NNP
,  ||| S:712 E:714 ||| ,
due  ||| S:714 E:718 ||| JJ
to  ||| S:718 E:721 ||| TO
non-anonymisation  ||| S:721 E:739 ||| JJ
of  ||| S:739 E:742 ||| IN
the  ||| S:742 E:746 ||| DT
data ||| S:746 E:750 ||| NNS
.  ||| S:750 E:752 ||| .
We  ||| S:752 E:755 ||| PRP
plan  ||| S:755 E:760 ||| VBP
to  ||| S:760 E:763 ||| TO
incorporate  ||| S:763 E:775 ||| VB
the  ||| S:775 E:779 ||| DT
results  ||| S:779 E:787 ||| NNS
of  ||| S:787 E:790 ||| IN
the  ||| S:790 E:794 ||| DT
mutation  ||| S:794 E:803 ||| JJ
analysis  ||| S:803 E:812 ||| NN
in  ||| S:812 E:815 ||| IN
the  ||| S:815 E:819 ||| DT
future ||| S:819 E:825 ||| NN
.  ||| S:825 E:827 ||| .
